Johnson & Johnson Launches Pulsed Field Ablation Technology in India with the VARIPULSE Platform
Advertisement
The VARIPULSE Platform integrates ablation and mapping capabilities into a single workflow through the CARTO 3 System.
Global Medtech company, Johnson & Johnson, has introduced the Pulsed Field Ablation (PFA) technology in India with the launch of the VARIPULSE Platform aimed at expanding treatment options for patients with atrial fibrillation (AFib).
The latest launch aimed at improving the treatment of AFib through a non-thermal energy approach that selectively targets cardiac tissue while minimising damage to surrounding structures.
AFib is an irregular and often rapid heartbeat caused by extra, uncoordinated electrical signals in the atria. The condition is associated with structural changes in the heart due to underlying conditions and lifestyle factors, and increases the risk of stroke, heart failure, and mortality.
As per reports, Atrial Fibrillation affects an estimated 50 million people worldwide, representing a burden comparable to heart failure, which impacts over 64 million people globally.
In India, AFib prevalence is estimated at 0.1% to 1.6% of the population, with approximately 5 million people currently living with the condition. Indian patients develop AFib nearly a decade earlier than those in Western populations, at an average age of around 55 years, extending the long-term disease burden.
Catheter ablation is a minimally invasive procedure used to restore normal heart rhythm by treating areas responsible for abnormal electrical signals.
Unlike conventional thermal ablation methods, PFA uses short, high-voltage electrical pulses to target cardiac cells by creating pores in cell membranes, leading to controlled cell death.
The technology is designed to improve procedural precision while reducing the risk of injury to adjacent tissues.
As per the company, the VARIPULSE Platform integrates ablation and mapping capabilities into a single workflow through the CARTO 3 System.
The system leverages 3D electroanatomical cardiac mapping technology to provide real-time visualisation and support physicians treating patients with atrial fibrillation.
The platform is designed to support precision, efficiency, reproducibility, and procedural accuracy. It is intended to provide minimal to no fluoroscopy exposure and is compatible with deep and/or conscious sedation.
As per the company, the platform has already received regulatory approval and is expected to support arrhythmia management and minimally invasive cardiac care.
Stay tuned for more such updates on Digital Health News
